Pernobon Injection (Polynate Calcium)
Calcium Folinate 3.2mg
Prescription medication
Samjin Pharmaceutical Co., Ltd.
MFDS item code 198600880 · Notified 1986.09.29 · Insurance code 647802471
Reduction of folate antagonist toxicity; treatment of advanced colorectal cancer in combination with 5-FU
This medication reduces toxicity caused by folate metabolism antagonists, alleviating the burden on patients. Additionally, it helps enhance therapeutic effects when used in conjunction with 5-Fluorouracil (5-FU) in the treatment of progressive colon cancer. In summary, it improves treatment stability by reducing toxicity from folate metabolism antagonists and enhances treatment effects when combined with colon cancer therapy.
(Injection) 1. Conventional methotrexate therapy: If adverse reactions occur at the usual dose of methotrexate (a folic acid antagonist), administer 6-12mg of folinate intramuscularly every 6 hours, 4 times per day. In the event of methotrexate overdose, administer an amount equal to the dose of methotrexate taken. 2. Methotrexate-folinate rescue therapy: Starting 3 hours after completion of methotrexate administration, administer 15mg of folinate intravenously every 3 hours for 9 doses, then intravenously or intramuscularly every 6 hours for 8 doses. If severe adverse reactions considered to be caused by methotrexate occur, increase the dose and extend the duration of treatment. 3. Combination therapy with 5-Fluorouracil (5-FU) for advanced colorectal cancer: Choose one of the following two regimens. 1) Administer 200mg/㎡ of calcium folinate intravenously slowly over at least 3 minutes, followed by intravenous administration of 370mg/㎡ of 5-FU. 2) Administer 20mg/㎡ of calcium folinate intravenously, followed by intravenous administration of 425mg/㎡ of 5-FU. Do not administer them simultaneously, as a precipitate may form between 5-FU and folinate. Continue the above treatment for 5 days and repeat it at 4-week intervals. (Tablets) In the event of an overdose of a folic acid antagonist (e.g., methotrexate), administer 10mg of folinate per m2 of body surface area orally every 6 hours as soon as possible (within 1 hour after the overdose) to reduce the serum methotrexate concentration to 10-8M/L or less. If gastrointestinal toxicity, nausea, or vomiting occurs, administer folinate parenterally. Analyze serum every 24 hours to determine creatinine and methotrexate concentrations. If, 24 hours later, the serum creatinine concentration has increased by 50% compared with the level before methotrexate administration, or if the serum methotrexate concentration at 24 hours is 5X10-6M/L or higher, administer a high dose of calcium folinate. Oral doses of 25mg or more are not recommended; administer parenterally. Provide fluids to maintain urine output of 1800-2000mL/㎡ per day, while alkalinizing the urine with sodium bicarbonate (maintain urine pH at 7.0 or higher) to increase the solubility of methotrexate and its metabolites until the methotrexate concentration is 5×10-8M/L(0.05μM/L).
This medication is not suitable for the treatment of pernicious anemia due to vitamin B12 deficiency or other megaloblastic anemias. Care is needed as hematologic status may improve while neurological symptoms progress. When using the injection, glass fragments may be introduced when cutting the ampoule, so care must be taken to ensure that no glass particles enter, especially when administering to children or the elderly. Certain cases of pregnant or breastfeeding women should avoid this medication, especially when used in combination with 5-FU. Caution is also warranted for women of childbearing potential or nursing mothers. This medication may cause allergic reactions such as urticaria or anaphylaxis, so immediate consultation with healthcare personnel is necessary if unusual symptoms occur. Pain at the injection site may occur, and symptoms such as fever or neurological disturbances may also develop. This medication reduces toxicity when used in combination with the anticancer drug methotrexate, so regular monitoring of blood methotrexate levels is required to determine the duration of therapy and dosage. If renal function is impaired or body fluid status is abnormal, drug clearance may be delayed, necessitating dosage adjustments. This medication shares transporters with methotrexate; hence, if there is resistance to methotrexate, there may also be resistance to this drug. If severe vomiting or difficulty in drug absorption occurs, administering it as an injection is preferable. When used with 5-FU, this medication may increase the effects and side effects of 5-FU, thus requiring frequent blood tests and liver function tests, with dosage adjustments of 5-FU if adverse reactions are significant. Additionally, this medication can lower the serum concentrations of drugs such as phenobarbital, phenytoin, and primidone, increasing the risk of seizures; thus, monitoring serum levels and adjusting doses are necessary. This medication contains calcium, so care must be taken not to exceed an intravenous administration rate of 160mg per minute, and intrathecal administration is prohibited. Store this medication out of the reach of children, sealing it in its original container, as transferring it to another container may lead to misuse or degradation of quality. Elderly patients may have altered responses due to decreased physiological function, so special caution is required during administration.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a sealed container that blocks light. Additionally, it is best to store the medication at room temperature in a place that is not too hot or too cold.
Colorless to light yellow transparent injection solution in brown ampoules
1mL-50 ampoules per box
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Calcium Folinate 3.2mg
Prescription medication
Samjin Pharmaceutical Co., Ltd.
Calcium Folinate 16mg
Prescription medication
Samjin Pharmaceutical Co., Ltd.

Calcium Folinate 5.4mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.
Calcium Folinate 106.7mg
Prescription medication
Samjin Pharmaceutical Co., Ltd.
Calcium Folinate 32mg
Prescription medication
Samjin Pharmaceutical Co., Ltd.
Calcium Folinate 53.4mg
Prescription medication
Samjin Pharmaceutical Co., Ltd.
Calcium Folinate 16.2mg
Prescription medication
Korea Pfizer Pharmaceutical Co., Ltd.
Calcium Folinate 10.8mg
Prescription medication
Korea Pfizer Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.